PerkinElmer to Provide Gilson with New Mass Spectrometry Technology
News Dec 16, 2009
PerkinElmer (UK) Ltd., a global leader focused on the health and safety of people and the environment, and Gilson, Inc., an industry leader in purification systems for liquid chromatography (LC) and solid phase extraction (SPE), today announced a mass spectroscopy (MS) collaboration to support pharmaceutical and biotech scientists. This collaboration will enable the two companies to provide new and enhanced solutions for fraction collection and liquid chromatography.
As part of the agreement, PerkinElmer will develop a dedicated single quadrupole mass spectrometer to be incorporated into Gilson’s preparative chromatography systems, enabling scientists to use the specificity of MS to improve the efficiency of their purification processes.
Gilson will integrate PerkinElmer’s MS technology with Gilson’s LC and fraction collection technology through Gilson’s proprietary Trilution software, bringing laboratory professionals enhanced signal specificity in their data. The use of MS detection provides additional sample insight as well as a high level of specificity that enhances the preparative system’s efficiency.
“PerkinElmer’s expertise and commitment to MS, combined with its well-established reputation in chromatography, makes the Company a strong partner of choice,” said Dennis Claspell, senior vice president sales and marketing, Gilson, Inc. “Our pharmaceutical and biotech customers demand expertise, reliability and performance. Through this reseller agreement, we will continue to provide Gilson customers with the best purification solutions on the market.”
“By fostering and developing collaborations with other technology leaders such as Gilson, PerkinElmer is able to provide scientists with the newest technologies and solutions they need to meet their most stringent analysis requirements,” notes Eric Ziegler, vice president, chromatography and mass spectrometry, PerkinElmer. “These collaborations are also a critical component of our long-term strategy to continue to expand PerkinElmer’s mass spectrometry offerings to key global market segments.”
Advanced Cancer Drug Study Highlights Need for Novel ApproachesNews
The pre-clinical findings, just published in Cell Chemical Biology, may lay the foundation for improving therapies for treatment-resistant, aggressive prostate cancer.READ MORE
Comments | 0 ADD COMMENT
18th International Conference and Exhibition on Analytical & Bioanalytical Chromatographic Techniques
Nov 02 - Nov 03, 2017
8th Edition of International Conference on Mass Spectromerty
Mar 12 - Mar 13, 2018